Tumors Harboring Braf Alterations clinical trials

Explore recruiting tumors harboring braf alterations clinical trials.

Recruiting tumors harboring braf alterations studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tumors Harboring Braf Alterations trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations

Spain, Italy, France, Germany, Sweden, Norway +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Tumors Harboring Braf Alterations trials by city

Tumors Harboring Braf Alterations in Toronto Tumors Harboring Braf Alterations in Vancouver Tumors Harboring Braf Alterations in Montreal Tumors Harboring Braf Alterations in Calgary Tumors Harboring Braf Alterations in Edmonton Tumors Harboring Braf Alterations in Ottawa Tumors Harboring Braf Alterations in Winnipeg Tumors Harboring Braf Alterations in Quebec City Tumors Harboring Braf Alterations in Hamilton Tumors Harboring Braf Alterations in Kitchener Tumors Harboring Braf Alterations in London Tumors Harboring Braf Alterations in Halifax Tumors Harboring Braf Alterations in New York Tumors Harboring Braf Alterations in Los Angeles Tumors Harboring Braf Alterations in Chicago Tumors Harboring Braf Alterations in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease